Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06702501 · ClinicalTrials.gov registry record · NA
The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)
A NA study of Heart Failure With Preserved Ejection Fraction, sponsored by Heart Failure Solutions.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06702501: Recruiting NA study of Heart Failure With Preserved Ejection Fraction, sponsored by Heart Failure Solutions.
NCT06702501 is a NA study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Heart Failure Solutions. The registered enrollment target is 10 participants, below the 2,288-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06702501, a NA study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Heart Failure Solutions.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The PeriCut early feasibility study will evaluate the safety and feasibility of successfully performing a minimally invasive pericardiotomy in patients with heart failure with preserved ejection fraction using the PeriCut Catheter System.
Primary Outcome
Characterize the incidence of serious device and procedure related safety events at 30 days post procedure
Conditions Studied
Interventions
- DEVICE PeriCut Catheter System performs minimally invasive pericardiotomy
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
What NCT06702501 shows while recruiting
NCT06702501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,288-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which PeriCut Catheter System performs minimally invasive pericardiotomy is the first listed.
NCT06702501 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06702501 about?
NCT06702501 is a clinical study titled "The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)". The PeriCut early feasibility study will evaluate the safety and feasibility of successfully performing a minimally invasive pericardiotomy in patients with heart failure with preserved ejection fraction using the PeriCut Catheter System.
What is the current status of trial NCT06702501?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-02-17. Estimated completion is 2026-06-01.
What conditions does trial NCT06702501 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT06702501?
The interventions under investigation include: PeriCut Catheter System performs minimally invasive pericardiotomy (DEVICE).
Who is sponsoring clinical trial NCT06702501?
This trial is sponsored by Heart Failure Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06702501 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06702501's enrollment target sits among peer trials
10 41st of 42 higher than 1 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
Transitions of Care Clinic (TOCC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI